Humalog (Insulin Lispro)

Humalog is indicated for use in several diabetic conditions where rapid glucose control is required, and it can be incorporated into individualized treatment plans.

• Type 1 diabetes mellitus as part of basal‑bolus insulin regimen.
• Type 2 diabetes mellitus when oral agents are insufficient or rapid‑acting insulin is needed.
• Post‑prandial glucose control in patients using multiple daily injections.
• Management of hyperglycemia during pregnancy (off‑label, based on clinical judgment).
• Intravenous insulin infusion for peri‑operative or critical‑care glucose management.
• Use in insulin pump therapy as a rapid‑acting bolus component.

• Insulin lispro is a rapid‑acting insulin analog that binds to the α‑subunit of the insulin receptor on muscle, adipose and hepatic cells. This binding activates the receptor’s intrinsic tyrosine kinase, initiating a cascade that translocates GLUT‑4 transporters to the cell membrane, enhancing glucose uptake, and suppresses hepatic gluconeogenesis. The molecular modifications of lispro reduce self‑association, allowing faster absorption after subcutaneous injection compared with regular human insulin.

Adverse reactions to Humalog may vary in frequency and severity.

Common

• Hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection site reactions such as redness, swelling, or itching.
• Lipodystrophy presenting as localized thickening or loss of subcutaneous fat.
• Weight gain associated with improved glycemic control.
• Nausea or abdominal discomfort that usually resolves without intervention.
• Headache or dizziness, often related to fluctuating blood glucose levels.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Persistent hyperglycemia indicating possible insulin resistance or dosing error.
• Acute respiratory distress or bronchospasm as part of a severe allergic response.

When prescribing or using Humalog, clinicians and patients should observe several precautionary measures to minimize risks and ensure effective therapy.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Adjust dose during periods of illness, stress, or changes in physical activity.
• Monitor blood glucose frequently, especially when initiating therapy or modifying the regimen.
• Educate patients on recognizing and treating hypoglycemia promptly.
• Avoid using Humalog in patients with known hypersensitivity to insulin lispro or its excipients.
• Consider pregnancy status; insulin requirements may change and close monitoring is required.
• Store the product according to manufacturer instructions, protecting it from extreme temperatures.

Humalog can interact with other medicines or substances that affect blood glucose levels or insulin action.

Avoid

• Concurrent use of other rapid‑acting insulins without dose adjustment, which may cause severe hypoglycemia.
• Beta‑blockers that mask hypoglycemia symptoms, increasing risk of unnoticed low glucose.
• MAO‑A inhibitors combined with sympathomimetic agents, potentially altering glucose metabolism.

Use with caution

• Oral antidiabetic agents such as sulfonylureas or meglitinides, which may potentiate hypoglycemia.
• Corticosteroids, which can raise blood glucose and require insulin dose increases.
• Alcohol intake, especially in excess, as it can cause delayed hypoglycemia after insulin administration.
• Thyroid hormones (e.g., levothyroxine) may increase insulin clearance, potentially requiring dose adjustment.